Editorial: Proteoglycans and Glycosaminoglycan Modification in Immune Regulation and Inflammation by Reijmers, Rogier M. et al.
EDITORIAL
published: 15 October 2020
doi: 10.3389/fimmu.2020.595867
Frontiers in Immunology | www.frontiersin.org 1 October 2020 | Volume 11 | Article 595867
Edited and reviewed by:
Silvano Sozzani,











This article was submitted to
Cytokines and Soluble Mediators in
Immunity,
a section of the journal
Frontiers in Immunology
Received: 17 August 2020
Accepted: 08 September 2020
Published: 15 October 2020
Citation:
Reijmers RM, Troeberg L, Lord MS
and Petrey AC (2020) Editorial:
Proteoglycans and
Glycosaminoglycan Modification in





Immune Regulation and Inflammation
Rogier M. Reijmers 1*, Linda Troeberg 2*, Megan S. Lord 3* and Aaron C. Petrey 4,5*
1 LUMICKS B.V., Amsterdam, Netherlands, 2Norwich Medical School, University of East Anglia, Norwich, United Kingdom,
3Graduate School of Biomedical Engineering, University of New South Wales Sydney, Sydney, NSW, Australia, 4University of
Utah Molecular Medicine Program, Salt Lake City, UT, United States, 5Division of Microbiology and Immunology, Department
of Pathology, University of Utah, Salt Lake City, UT, United States
Keywords: glycosaminoglycan (GAG), proteoglycans (PG), immune response, inflammation, heparan sulfate (HS),
chondroitin sulfate (CS), dermatan sulfate (DS), hyaluronan
Editorial on the Research Topic
Proteoglycans and GlycosaminoglycanModification in Immune Regulation and Inflammation
While many publications cover proteoglycan and glycosaminoglycan (GAG) research each year,
to date there is still limited knowledge about the specific roles of these macromolecules in the
regulation of immune responses and homeostasis. More specifically, the transcriptional control
is understudied and largely unknown (1). For this reason, we initiated this Research Topic
for Frontiers in Immunology, and challenged scientists to provide findings that uncover novel
functions or summarize recent progress that connect these two fields of research. Our collection
of 16 manuscripts consists of 7 Original Research papers, one Perspective, one Mini Review, and
7 Reviews covering different aspects of proteoglycan biology in immune processes, which are
summarized below.
Proteoglycans are ubiquitously expressed intracellularly, on the cell surface and in the
extracellularmatrix. Attached to their core are one or amultitude of covalently linked linear anionic
GAGs, which are subject to an array of synthetic and post-synthetic enzymatic modifications,
leading to an almost infinite combination of configurations, each potentially harboring specific
functions (2). As such, precise GAG modifications have been attributed to drive interactions with
immune cells, pathogens, and specific protein ligands, while functions have also been attributed
to the core proteins. Likewise, the immune system is extremely diverse with many different cell
types and immunomodulators, such as chemokines and cytokines, each having specific and unique
functions. All of these components need to be kept in strict balance and require tight spatiotemporal
regulation to avoid development of autoimmunity or cancer, while combatting a limitless number
of pathogens. Understanding this complexity is the greatest challenge in the field and requires
detailed structural analysis of GAGs and proteoglycans (3).
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Rajarathnam and Desai reviewed recent progress in
understanding the molecular basis of chemokine interactions
with GAGs and their CXCR1 and CXCR2 receptors. They argue
that the range of GAG-binding affinities and geometries confers
remarkable selectivity on the in vivo phenotype of individual
chemokines, and that understanding these interactions is
critical for clinical application. Crijns et al. more broadly
address chemokine-GAG interactions, and suggest that limiting
inflammation using different approaches like chemokine-derived
GAG-binding peptides or dominant-negative chemokine
mutants, might be beneficial, especially if required to reduce the
inflammatory response, rather than completely eliminating it.
Specific effects of GAGs on inflammatory processes were
addressed by several authors. For example, Talsma et al. extended
our understanding of GAG effects on complement activation
by demonstrating that heparin/heparan sulfate oligosaccharides
inhibit the lectin pathway via inhibiting the activity of serine
protease MASP-2 that cleaves C4. This work may enable the
development of glycan-based inhibitors of the lectin pathway
with therapeutic value. Arokiasamy, King et al. profiled the
glycocalyx of lymphatic vessel endothelial cells, which is less
well-understood than the glycocalyx associated with vascular
endothelial cells. They showed that the lymphatic glycocalyx
of murine cremaster muscles is remodeled in response to
TNF-mediated inflammation. Blocking heparanase-mediated
degradation of HS had no effect on neutrophil migration
through the lymphatic vessels; but reduced lymphatic drainage
of interstitial fluid. The responses and function of the lymphatic
glycocalyx is thus distinct from that of blood vessels. El Masri
et al. explored the role of SULFs in inflammation. Despite
clear evidence for critical functions of these enzymes in various
pathologies including cancer, the roles of SULFs in inflammatory
processes are under-appreciated. To advance this field, further
investigations are needed to fully understand their spatial and
temporal expression and activity. How this could be strategically
advanced in the near future is discussed in this Perspective article.
Use of disease models is progressing our understanding of
the role of GAGs in complex in vivo scenarios. Pessentheiner
et al. summarize the broad role of proteoglycans in obesity-
related inflammation. Each class of proteoglycan is discussed,
including their enzymatic modifications, and key clinical studies
are highlighted implicating proteoglycans as therapeutic targets
and biomarkers. Despite limited knowledge of syndecans in
obesity-related inflammation, it is clear that syndecans are
major players in inflammation. Gopal concisely reviewed the
characteristics of syndecans, especially syndecan-1, -2 and -4,
explaining their diverse role at the cell surface or as soluble
proteins. Arokiasamy, Balderstone et al. focused on the role
of syndecan-3 in inflammation and angiogenesis, discussing
its impact in several distinct disease types and emphasizing
that interactions with the GAG chains make syndecan-3 an
inflammatory mediator.
In addition to research on HS, we are beginning to appreciate
the roles of chondroitin sulfate (CS) in regulating inflammation.
Hatano and Watanabe reviewed the roles of CS produced by
antigen presenting cells, in contrast to the more widely studied
roles of heparan sulfate (HS) and hyaluronan (HA). Importantly,
this review suggests a structure-function relationship for CS
based on sulfation with highly sulfated CS, such as CS-C, CS-
D, and CS-E, possessing anti-inflammatory properties while the
lesser sulfated CS-A possesses both pro- and anti-inflammatory
properties. In addition, chain length is a determinant of function
with oligosaccharides exhibiting pro-inflammatory properties.
Wight et al. provide a comprehensive review on the regulatory
roles of the HA-binding proteoglycan versican in the context
of immunity and inflammation. The authors summarize how
versican and its five different isoforms vary in function, and
though not all contain CS chains, each mediates complex roles
from development to inflammation by virtue of interacting with
a host of diverse immune receptors. They provide insight into
cell-type specific functions of versican and highlight how CS
containing glycoforms allow versican to function as either a pro-
or anti-inflammatory proteoglycan.
Although HA lacks the sulfation shared by the other GAGs,
investigation into its regulatory role in inflammatory processes
continues to reveal unexpected findings. Dong et al. report a
previously unknown link between the HA receptor CD44 and
clearance of lung surfactant by alveolar macrophages (AM),
which constitutively bind to HA. Loss of CD44 in mice leads to
reduced numbers of AMs, and dysregulation of genes involved
in cholesterol metabolism. In addition, CD44 deficiency results
in a buildup of lipid surfactant, foam-cell AMs, and oxidized
lipids which exacerbate lung damage and inflammation. Reeves
et al. demonstrate that RSV infection of pediatric human lung
fibroblasts results in the formation of an HA-enriched ECM
capable of recruiting mast cells and augmenting expression of
mast cell proteases. Further, by disrupting HA synthesis or
HA binding, the authors demonstrate that increased protease
expression depends on mast cell interaction with the HA-matrix
produced by infected cells.
Besides the impact on cells and immune modulators, effects
of GAGs on bacterial pathogenesis were also explored. Martín
et al. report that adhesion of L. salivarius Lv72 to HeLa
cells induced expression of proteoglycan core proteins but
reduced glycosaminoglycan chain biosynthesis by the HeLa cells.
In addition, L. salivarius Lv72 increased expression of oppA
which aids in adhesion to mucosal cells. These results suggest
communication between mucosa and microbiota. Galeev et al.
demonstrated that proteoglycans not only play a role in bacterial
adhesion and uptake by epithelial cells, but that they also play
a critical role in the survival of bacteria once internalized via
control of intracellular trafficking and endo-lysosomal fusion.
Clinical translation of GAG-based therapies is an exciting
challenge. PG545, a synthetic heparanase inhibitor, has been
demonstrated to affect tumor viability by preventing angiogenesis
and non-neoplastic inflammatory disorders. PG545 acts through
competing for GAG binding, and Koliesnik et al. show
that it selectively induces Treg development and inhibits the
formation of Th17 cells in vitro and during in vivo delayed
type hypersensitivity (DTH). Unexpectedly, these effects were
independent of heparanase, but the results support clinical
application of PG545 in inflammatory responses associated
with DTH. Furthermore, use of human milk glycans such
as HA have captured attention for their potential as natural
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products to enhance immune responses and their safety as
therapeutic modalities. Kim and de la Motte summarize several
pre-clinical studies highlighting the known roles of HA in
intestinal host defense, detailing the receptors which mediate
downstream mechanisms activated by exogenous HA including
barrier function and anti-microbial effects.
Our Research Topic underscores the diverse role that
proteoglycans have in inflammation and how they control
different aspects of immunological processes. However,
it also demonstrates that there is still much to discover
about the specific mechanisms of their action, including
transcriptional and translational regulation of proteoglycan and
GAG biosynthesis (1).
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and
intellectual contribution to the work, and approved it
for publication.
ACKNOWLEDGMENTS
We would like to thank all authors for their contribution
to our Research Topic. This work was supported by Versus
Arthritis (grant 21245, LT) and National Institutes of Health
(HL135265, AP).
REFERENCES
1. Weiss RJ, Spahn PN, Toledo AG, Chiang AWT, Kellman BP, Li J, et al. ZNF263
is a transcriptional regulator of heparin and heparan sulfate biosynthesis. Proc
Natl Acad Sci USA. (2020) 117:9311–7. doi: 10.1073/pnas.1920880117
2. Bishop JR, Schiksz M, Esko JD. Heparan sulphate proteoglycans fine-tune
mammalian physiology. Nature. (2007) 446:1030–7. doi: 10.1038/nature05817
3. Kjellén L, Lindahl U. Specificity of glycosaminoglycan-protein interactions.
Curr Opin Struct Biol. (2018) 50:101–8. doi: 10.1016/j.sbi.2017.12.011
Conflict of Interest: RR was employed by the company LUMICKS. ML is a
Director of Glycos Pty Ltd, which is focused on the generation of bioengineered
glycosaminoglycans as therapeutics.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2020 Reijmers, Troeberg, Lord and Petrey. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 3 October 2020 | Volume 11 | Article 595867
